Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19844284 | 0.93 | ERBB2 (0.35) | ERBB2CYP1A2FYNMAOAACHE | |
| SCHEMBL18904357 | 0.91 | ERBB2 (0.34) | ERBB2CYP1A2FYNMAOAACHE | |
| SCHEMBL12796377 | 0.89 | GSTP1 (0.32) | ERBB2CYP1A2FYNMAOAACHE | |
| SCHEMBL12796343 | 0.89 | GPR84 (0.38) | CYP1A2GPR84GSTP1HDAC4HDAC2 | |
| SCHEMBL18904347 | 0.88 | GSTP1 (0.37) | CYP1A2GPR84GSTP1HDAC4HDAC2 | |
| SCHEMBL18904378 | 0.88 | ALDH1A1 (0.36) | ERBB2CYP1A2FYNMAOAACHE | |
| SCHEMBL12796369 | 0.88 | TSHR (0.35) | CYP1A2GPR84GSTP1HDAC4HDAC2 | |
| SCHEMBL12796335 | 0.87 | GSTP1 (0.36) | CYP1A2GPR84GSTP1HDAC4HDAC2 | |
| SCHEMBL12796344 | 0.86 | HDAC4 (0.36) | CYP1A2GPR84GSTP1HDAC4HDAC2 | |
| SCHEMBL18904362 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10720473-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-07-21 | — | — | US | disclosed |
| US-20190296091-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-09-26 | — | — | US | disclosed |
| US-10361252-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-07-23 | — | — | US | disclosed |
| US-20180040827-A1 | ORGANIC LIGHT EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-02-08 | — | — | US | disclosed |
| US-20180040827-A1 | ORGANIC LIGHT EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-02-08 | — | — | US | disclosed |
| US-20170154931-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20170154931-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-8395144-B2 | Anthracene derivatives and organic electroluminescent device using same | DOOSAN CORPORATION (KR) | 2013-03-12 | — | — | US | disclosed |
| US-20110057182-A1 | ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | DOOSAN CORPORATION (KR) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110057182-A1 | ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | TRPA1, AHR, ORAI2 | ERBB2 2775/4885CYP1A2 29/4885FYN 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.